Literature DB >> 14749703

Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia.

M D Tischkowitz1, N V Morgan, D Grimwade, C Eddy, S Ball, I Vorechovsky, S Langabeer, R Stöger, S V Hodgson, C G Mathew.   

Abstract

Fanconi anemia (FA) is an autosomal recessive chromosomal instability disorder caused by mutations in one of seven known genes (FANCA,C,D2,E,F,G and BRCA2). Mutations in the FANCA gene are the most prevalent, accounting for two-thirds of FA cases. Affected individuals have greatly increased risks of acute myeloid leukemia (AML). This raises the question as to whether inherited or acquired mutations in FA genes might be involved in the development of sporadic AML. Quantitative fluorescent PCR was used to screen archival DNA from sporadic AML cases for FANCA deletions, which account for 40% of FANCA mutations in FA homozygotes. Four heterozygous deletions were found in 101 samples screened, which is 35-fold higher than the expected population frequency for germline FANCA deletions (P<0.0001). Sequencing FANCA in the AML samples with FANCA deletions did not detect mutations in the second allele and there was no evidence of epigenetic silencing by hypermethylation. However, real-time quantitative PCR analysis in these samples showed reduced expression of FANCA compared to nondeleted AML samples and to controls. These findings suggest that gene deletions and reduced expression of FANCA may be involved in the promotion of genetic instability in a subset of cases of sporadic AML.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749703     DOI: 10.1038/sj.leu.2403280

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  31 in total

1.  Mutations in Fanconi anemia genes and the risk of esophageal cancer.

Authors:  Mohammad R Akbari; Reza Malekzadeh; Pierre Lepage; David Roquis; Ali R Sadjadi; Karim Aghcheli; Abbas Yazdanbod; Ramin Shakeri; Jafar Bashiri; Masoud Sotoudeh; Akram Pourshams; Parviz Ghadirian; Steven A Narod
Journal:  Hum Genet       Date:  2011-01-30       Impact factor: 4.132

Review 2.  Advances in the understanding of the Fanconi anemia tumor suppressor pathway.

Authors:  Anna Pickering; Jun Zhang; Jayabal Panneerselvam; Peiwen Fei
Journal:  Cancer Biol Ther       Date:  2013-09-09       Impact factor: 4.742

Review 3.  Molecular pathogenesis of Fanconi anemia.

Authors:  Natalie Collins; Gary M Kupfer
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

Review 4.  Fanconi anaemia: from a monogenic disease to sporadic cancer.

Authors:  Antonio Valeri; Sandra Martínez; José A Casado; Juan A Bueren
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

5.  The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair.

Authors:  Huimei Lu; Xu Guo; Xiangbing Meng; Jingmei Liu; Chris Allen; Justin Wray; Jac A Nickoloff; Zhiyuan Shen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 6.  Susceptibility pathways in Fanconi's anemia and breast cancer.

Authors:  Alan D D'Andrea
Journal:  N Engl J Med       Date:  2010-05-20       Impact factor: 91.245

7.  Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

Authors:  Richard D Kennedy; Clark C Chen; Patricia Stuckert; Elyse M Archila; Michelle A De la Vega; Lisa A Moreau; Akiko Shimamura; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2007-04-12       Impact factor: 14.808

Review 8.  Fanconi anaemia and cancer: an intricate relationship.

Authors:  Grzegorz Nalepa; D Wade Clapp
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

9.  FANCA safeguards interphase and mitosis during hematopoiesis in vivo.

Authors:  Zahi Abdul-Sater; Donna Cerabona; Elizabeth Sierra Potchanant; Zejin Sun; Rikki Enzor; Ying He; Kent Robertson; W Scott Goebel; Grzegorz Nalepa
Journal:  Exp Hematol       Date:  2015-09-11       Impact factor: 3.084

Review 10.  Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.

Authors:  Paul R Andreassen; Keqin Ren
Journal:  Curr Cancer Drug Targets       Date:  2009-02       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.